Action NKGN NKGEN BIOTECH, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues NKGen Biotech, Inc. Nyse

Actions

NKGN

US65488A1016

Marché Fermé - Nyse
Autres places de cotation
 22:00:00 29/04/2024 		Varia. 5j. Varia. 1 janv.
1,64 USD +1,86 % Graphique intraday de NKGen Biotech, Inc. +11,56 % -80,24 %
29/04 Nkgen Biotech annonce l'approbation par la FDA de son dossier d'Investigational New Drug (IND) pour la thérapie cellulaire SNK01 dans le traitement de la maladie de Parkinson CI
18/04 NKGen Biotech, Inc. annonce sa prochaine présentation sur la thérapie à base de cellules NK SNK01 dans les maladies neurodégénératives lors du 12ème sommet annuel sur le développement des médicaments pour la maladie d'Alzheimer et de Parkinson. CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
NKGen Biotech, Inc. announced that it has received $5 million in funding
NKGen Biotech, Inc. announced that it has received $0.5 million in funding from AJB Capital Investments LLC, Sandia Investment Managment LP, Diametric Capital, LP
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's disease at the Tau2024 Global Conference
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference
NKGen Biotech, Inc. announced that it expects to receive $0.33 million in funding from FirstFire Capital Management LLC
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
Exchange-Traded Funds Lower, Equity Futures Flat Pre-Bell Friday
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NKGN
  4. Action NKGN
  5. Actualités NKGen Biotech, Inc.
  6. Autres langues